Vorinostat (suberoylanilide hydroxamic acid) is the first US Food and Drug Administration (FDA)-approved histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphomas (CTCLs) who have progressive, persistent, or recurrent disease on or following two systemic therapies. In two phase II trials, vorinostat was safe and effective at an oral dose of 400mg/day, with an overall response rate of 24-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome.
brief overview of the biology of HDACs and HDAC-Is, as well as pre-clinical and clinical studies of vorinostat in CTCL.
Biology of Histone Deacetylases and Their Inhibitors
HDACs and histone acetylases (HATs) are key enzymes that remove or add acetyl groups to proteins including histones. To date, four classes of HDAC have been identified (see Table 1 ).
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Class I human HDACs (HDACs 1, 2, 3, and 8) are small, with an approximate molecular mass of 22-55kDa, and are homologous to the yeast HDAC Rpd3. Class II HDACs (HDACs 4, 5, 6, 7, 9, and 10) some shuttle between the nucleus and the cytoplasm, whereas others are primarily cytoplasmic. In cancer cells, class I and II HDACs have been shown to be over-expressed, aberrantly recruited to oncogenic transcription factors, and mutated. As such, they represent potential key targets for small-molecule inhibitors.
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There are currently five classes of HDAC-I grouped according to their chemical structure and affinity for different HDACs (see Table 2 ). angiogenic and immunomodulatory activity that may play an important role in mediating their antitumor effects.
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Mechanisms of Action of Vorinostat in Cutaneous T-Cell Lymphomas
Selective Induction of Apoptosis 
Inhibition of Angiogenesis
Angiogenesis is a key process during tumor development and 
Increased Accumulation of Acetylated Histones
Histone acetylation is a defining event after treatment with HDAC-Is, and can thus be used as an indicator of HDAC-I activity in both normal and tumor cells. This has led to the widespread use of histone acetylation in 
Upregulation of Pro-apoptotic Proteins
The cyclin-dependent kinase (CDK) inhibitor p21 (WAF1/CIP1) is one of the most commonly reported genes induced by HDAC-I. 32 P21
regulates both the cell cycle and apoptosis. 29 In CTCL, although upregulation of p21 occurred in response to vorinostat, immunoblot analysis showed that this effect was independent of the tumor suppressor p53. 
Dose-ranging Phase II Trial of Oral Vorinostat in Patients with Cutaneous T-cell Lymphomas
A single-center phase II dose-ranging trial was initiated to determine response rate and the duration, safety, and tolerability of oral vorinostat in 33 heavily pre-treated patients with refractory or relapsed CTCL (stages IA-IVB). 6 Eighty-five percent of the patients had advanced-stage CTCL and one-third had SS. Although patients were only required to be unresponsive to ≤1 conventional therapy, the patients had a median of five prior therapies (range: one to 15). Of the 33 patients, 29 had received prior chemotherapy (22 bexarotene and 14 denileukin diftitox). The patients who enrolled were treated with one of three oral dosing schedules, and their demographics such as age and gender were similar. The first cohort received 400mg/day, the
Benefits of Vorinostat in Treating Advanced Cutaneous T-cell Lymphoma
second received 300mg twice daily (bid) for four days with rest for four days, and the third received 300mg bid for 14 days with rest for seven days followed by 200mg bid. The clinical response for each cohort and suggested dose modification schedule are shown in Table   3 . The primary efficacy end-point of the study was complete response (CR) and partial response (PR) rate. Secondary end-points included time to progressive disease, response duration, pruritus relief, and safety. The response to therapy was categorized according to the Physician's Global Assessment for CR, PR, stable disease (SD) or progressive disease (PD). 38 Skin involvement was assessed as body surface area (BSA) involvement with patch, plaque, or tumor disease.
Considering unique patients for an intent-to-treat analysis, eight out of 33 patients (24%) achieved a documented PR, with no CRs. Patients with prior use of HDAC-Is or anticancer treatment within three weeks of study entry were excluded.
Of the patients with treatment-refractory advanced MF/SS (≥stage IIB), 30% had ≥1 PR, and one patient with facial tumors had a complete long-lasting response. The median time to response was less than two months. Clinically long-lasting responses were observed. Median response duration and time to progression in advanced-stage (at least IIB) responders were not reached, but were estimated to be ≥6.1 and 9.8 months, respectively. Median time to progression in all patients was 4.9 months. Vorinostat provided pruritus relief in 32% of evaluable patients with baseline pruritus, including 25% of those who did not Hematological Cancer increase in creatinine (15%), anemia (1%), and chills (12%). Most were ≤grade 2. Drug-related ≥grade 3 events included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%).
There were three deaths in the study. 
